ALQGC — Quantum Genomics SA Share Price
0.000.00%
Last trade - 00:00- €4.10m
- €3.27m
- €0.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0.03 | ||
| PEG Ratio (f) | 0 | ||
| EPS Growth (f) | 152.29% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.39 | ||
| Price to Tang. Book | 9.39 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 407.45 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -132.6% | ||
| Return on Equity | -155.28% | ||
| Operating Margin | -31593.84% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | 1.2 | 0.12 | 0.6 | 0.01 | 145 | 20 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | -87.74 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Quantum Genomics SA is a France-based company. The Company is a biopharmaceutical company dedicated to developing new therapies for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure. Its main activity is in research and development of new therapies for the treatment of hypertension, BAPAI (Brain Aminopeptidase A Inhibitors) oriented in the field of cardiovascular diseases, especially high blood pressure and heart failure. The Company also co-develops products with academic teams, biotechnological research entities, and some of the pharmaceutical and bio-science companies. The Company is involved in four research programs. Quantum Genomics also collaborates with Center for Clinical Investigation 9201 APHP / INSERM of the Georges Pompidou European Hospital in Paris, among others.
Directors
- Lionel Segard CHM (53)
- Jeanphilippe Milon CEO (61)
- Benoit Gueugnon VFN
- Fabrice Balavoine VRD
- Bruno Besse OTH
- Carole Wassermann DRC
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 23rd, 2005
- Public Since
- July 28th, 2009
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 34,854,981
- Address
- 33 rue Marbeuf, PARIS, 75008
- Web
- https://quantum-genomics.com/
- Phone
- +33 185347770
- Auditors
- Deloitte & Associes
Upcoming Events for ALQGC
Similar to ALQGC
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Acticor Biotech SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
FAQ
What is the Quantum Genomics SA share price?
As of Today at 19:17 UTC, shares in Quantum Genomics SA are trading at €0.12. This share price information is delayed by 15 minutes.
How has the Quantum Genomics SA share price performed this year?
Shares in Quantum Genomics SA last closed at €0.12 and the price had moved by -14.41% over the past 365 days. In terms of relative price strength the Quantum Genomics SA share price has underperformed the FTSE Global All Cap Index by -19.65% over the past year.
What are the analyst and broker recommendations for Quantum Genomics SA?
The overall consensus recommendation for Quantum Genomics SA is Strong Sell. You can view the full broker recommendation list by unlocking its StockReport.
What is the Quantum Genomics SA dividend yield?
Quantum Genomics SA does not currently pay a dividend.
Does Quantum Genomics SA pay a dividend?
Quantum Genomics SA does not currently pay a dividend.
When does Quantum Genomics SA next pay dividends?
Quantum Genomics SA does not currently pay a dividend.
How do I buy Quantum Genomics SA shares?
To buy shares in Quantum Genomics SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Quantum Genomics SA?
As of the previous close price of €0.12, shares in Quantum Genomics SA had a market capitalisation of €4.10m.
Where are Quantum Genomics SA shares listed?
Here are the trading details for Quantum Genomics SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ALQGC
What kind of share is Quantum Genomics SA?
Based on an overall assessment of its quality, value and momentum Quantum Genomics SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Quantum Genomics SA share price forecast for 2024?
The analyst consensus target price for shares in Quantum Genomics SA is €10.00. That is 8403.4% above the last closing price of €0.12.
Analysts covering Quantum Genomics SA currently have a consensus Earnings Per Share (EPS) forecast of €4.65 for the next financial year.
What is the trend in the Quantum Genomics SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Quantum Genomics SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -4.58%.
As of the last closing price of €0.12, shares in Quantum Genomics SA were trading -3.55% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Quantum Genomics SA PE Ratio?
The Quantum Genomics SA PE ratio based on its reported earnings over the past 12 months is 0.03. The shares last closed at €0.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Quantum Genomics SA?
Quantum Genomics SA's management team is headed by:
- Lionel Segard - CHM
- Jeanphilippe Milon - CEO
- Benoit Gueugnon - VFN
- Fabrice Balavoine - VRD
- Bruno Besse - OTH
- Carole Wassermann - DRC